Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
AIDS [[electronic resource]]
| AIDS [[electronic resource]] |
| Autore | Aggleton Peter |
| Pubbl/distr/stampa | Hoboken, : Taylor and Francis, 1995 |
| Descrizione fisica | 1 online resource (237 p.) |
| Disciplina | 362.1/969792 |
| Altri autori (Persone) |
DaviesPeter (Peter M.)
HartGraham <1957-> |
| Collana | Social Aspects of AIDS |
| Soggetto topico |
AIDS (Disease)
AIDS (Disease) - Social aspects HIV Infections Sociology Slow Virus Diseases Probability Acquired Immunodeficiency Syndrome Risk Social Environment Virus Diseases Statistics as Topic Lentivirus Infections Sexually Transmitted Diseases, Viral Mathematical Concepts Social Sciences Immunologic Deficiency Syndromes Phenomena and Processes Sexually Transmitted Diseases Anthropology, Education, Sociology and Social Phenomena Diseases Health Care Evaluation Mechanisms Retroviridae Infections Immune System Diseases Epidemiologic Methods Quality of Health Care Investigative Techniques Public Health RNA Virus Infections Environment and Public Health Analytical, Diagnostic and Therapeutic Techniques and Equipment Health Care Quality, Access, and Evaluation Health Care Communicable Diseases Health & Biological Sciences |
| Soggetto genere / forma | Electronic books. |
| ISBN |
9982-19-047-4
0-203-36253-5 1-135-74692-3 1-280-02179-9 9786610021796 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Book Cover; Title; Contents; Preface; Reputedly Effective Risk Reduction Strategies and Gay Men; HIV-Related Discrimination in Medical Teaching Texts; Travel, Sexual Behaviour and Gay Men; Sexual Behaviour in Gay Men: Towards a Sociology of Risk; Framing Difference: Sexuality, AIDS and Organization; Towards Effective Inter vention: Evaluating HIV Prevention and Sexual Health Education Interventions; Communities, Governments and AIDS: Making Partnerships Work; Socially Apart Youth: Priorities for HIV Prevention
Theorizing and Researching 'Risk': Notes on the Social Relations of Risk in Heroin Users' LifestylesSex, Love and Seropositivity: Balancing the Risks; One of Us, One of Them, or One of Those? The Construction of Identity and Sexuality in Relation to HIV/AIDS; Sexuality, Identity and Community; Reflections on the MESMAC Project; Discourses of Power and Empowerment in the Fight Against HIV/AIDS in Africa; Notes on Contributors; Index |
| Record Nr. | UNISA-996207278803316 |
Aggleton Peter
|
||
| Hoboken, : Taylor and Francis, 1995 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
AIDS epidemiology : a quantitative approach / / Ron Brookmeyer, Mitchell H. Gail
| AIDS epidemiology : a quantitative approach / / Ron Brookmeyer, Mitchell H. Gail |
| Autore | Brookmeyer Ron |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | New York ; , : Oxford University Press, , 2023 |
| Descrizione fisica | 1 online resource (371 p.) |
| Disciplina | 614.5/993 |
| Collana | Oxford scholarship online |
| Soggetto topico |
AIDS (Disease) - Epidemiology
Biometry Epidemiology - Statistical methods Acquired Immunodeficiency Syndrome - epidemiology Epidemiologic Methods |
| ISBN |
0-19-773738-2
1-280-52629-7 9786610526291 0-19-974874-8 1-4237-6354-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- 1. INTRODUCTION -- 1.1 Brief History -- 1.2 HIV Virus and Its Clinical Effects -- 1.3 Measuring the Epidemic -- 1.4 Worldwide Scope of the Epidemic -- 2. RISK FACTORS FOR INFECTION AND THE PROBABILITY OF HIV TRANSMISSION -- 2.1 Introduction -- 2.2 Studies of AIDS Patients -- 2.3 Case-Control and Cohort Studies to Identify Risk Factors -- 2.4 Risks from Point Exposures -- 2.5 Sexual Transmission and Partner Studies -- 3. SURVEYS TO DETERMINE SEROPREVALENCE AND SEROINCIDENCE -- 3.1 Introduction -- 3.2 Estimating Seroprevalence Rates from Representative (Probability-Based) Samples -- 3.3 Surveys of Selected Subpopulations -- 3.4 Estimating National Seroprevalence from Surveys of Selected Subpopulations -- 3.5 Estimating HIV Incidence from Survey Data -- 4. THE INCUBATION PERIOD DISTRIBUTION -- 4.1 Introduction and Historical Overview -- 4.2 Mathematical Models for the Incubation Period Distribution -- 4.3 Retrospective Data on AIDS Cases -- 4.4 Prevalent Cohort Studies -- 4.5 Studies with Doubly Censored and Interval Censored Data -- 4.6 Deconvolution Methods (Back-Calculating the Incubation Distribution) -- 4.7 Duration of the Pre-Antibody Phase -- 4.8 Synthesis of Knowledge of the Incubation Period Distribution -- 5. COFACTORS AND MARKERS -- 5.1 Introduction -- 5.2 Cofactors and Doubly Censored Data -- 5.3 Cofactors and Prevalent Cohort Studies -- 5.4 Cofactors and Retrospective Studies of Cases -- 5.5 Markers as Prognostic Factors -- 5.6 The Marker Trajectory -- 5.7 Other Uses of Markers -- 5.8 Variability of Markers -- 5.9 Synthesis of Knowledge of Cofactors and Markers -- 6. SCREENING AND ACCURACY OF TESTS FOR HIV -- 6.1 Introduction -- 6.2 Sensitivity, Specificity, and Related Measures of Accuracy for Diagnostic Tests -- 6.3 Screening Applications and Positive Predictive Value -- 6.4 Safety of the Blood Supply.
6.5 Assays for Live Virus, for HIV Antigen, and for HIV Genome -- 7. STATISTICAL ISSUES IN SURVEILLANCE OF AIDS INCIDENCE -- 7.1 Introduction -- 7.2 AIDS Incidence Data -- 7.3 Statistical Analysis of Reporting Delays -- 7.4 Underreporting of AIDS Cases -- 7.5 Changes in the Surveillance Definition -- 7.6 Empirical Extrapolation of AIDS Incidence -- 8. BACK-CALCULATION -- 8.1 Introduction -- 8.2 Deterministic Deconvolution -- 8.3 Statistical Deconvolution -- 8.4 Uncertainty in Back-Calculation -- 8.5 Back-Calculation for Investigating Hypotheses About the Infection Rate -- 8.6 Generalized Back-Calculation: Extension to Account for Nonstationary Incubation Distributions -- 8.7 Application to the U.S. AIDS Epidemic -- 8.8 Technical Notes -- 9. EPIDEMIC TRANSMISSION MODELS -- 9.1 Introduction -- 9.2 A Closed Two-Compartment Model -- 9.3 Generalizations of the Closed Two-Compartment Model -- 9.4 Heterogeneous Subgroups and the Importance of Mixing Patterns -- 9.5 Evaluating Prevention Strategies -- 9.6 Stochastic Epidemic Models -- 9.7 Comparing Parameters in Epidemic Models with Empirical Estimates of Doubling Times and HIV Prevalence Ratios -- 9.8 Discussion -- 10. SYNTHESIZING DATA SOURCES AND METHODS FOR ASSESSING THE SCOPE OF THE EPIDEMIC -- 10.1 Introduction -- 10.2 Combining Data and Methods -- 10.3 Forecasting in Developing Countries -- 10.4 Forecasting Pediatric AIDS -- 10.5 Forecasting for Small Areas -- 11. DEVELOPING AND EVALUATING NEW THERAPIES AND VACCINES -- 11.1 Introduction -- 11.2 History of the Development of AZT -- 11.3 Approaches to Therapy Based on the Pathophysiology of HIV Disease -- 11.4 Observational Studies -- 11.5 Special Problems and Design Issues in Clinical Trials for HIV Disease -- 11.6 Vaccine Trials -- References -- Index -- A -- B -- C -- D -- E -- F -- G -- H -- I -- K -- L -- M -- N -- O -- P -- Q -- R -- S -- T -- U. V -- W -- Z. |
| Record Nr. | UNINA-9910968334403321 |
|
Brookmeyer Ron
|
||
| New York ; , : Oxford University Press, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Alcohol consumption and cancer risk : understanding possible causal mechanisms for breast and colorectal cancers
| Alcohol consumption and cancer risk : understanding possible causal mechanisms for breast and colorectal cancers |
| Pubbl/distr/stampa | [Place of publication not identified], : Agency for Healthcare Research and Quality, 2010 |
| Descrizione fisica | 1 online resource (ix, 81 p.) |
| Collana |
AHRQ Publication
Evidence Report/Technology Assessment |
| Soggetto topico |
Risk
Breast Diseases Drinking Behavior Colonic Diseases Intestinal Neoplasms Causality Neoplasms by Site Rectal Diseases Gastrointestinal Neoplasms Neoplasms Probability Intestinal Diseases Behavior Epidemiologic Factors Skin Diseases Disease Behavior and Behavior Mechanisms Gastrointestinal Diseases Statistics as Topic Skin and Connective Tissue Diseases Digestive System Neoplasms Quality of Health Care Public Health Digestive System Diseases Environment and Public Health Epidemiologic Methods Health Care Quality, Access, and Evaluation Health Care Evaluation Mechanisms Delivery of Health Care Investigative Techniques Diagnostic Techniques and Procedures Breast Neoplasms Risk Factors Colorectal Neoplasms Alcohol Drinking Medicine Health & Biological Sciences Oncology |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910703239203321 |
| [Place of publication not identified], : Agency for Healthcare Research and Quality, 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
American journal of epidemiology
| American journal of epidemiology |
| Pubbl/distr/stampa | [Baltimore, Md.], : Johns Hopkins University School of Hygiene and Public Health |
| Descrizione fisica | 1 online resource (volumes) |
| Disciplina | 614 |
| Soggetto topico |
Epidemiology
Public health Epidemiologic Methods Public Health epidemiology public health |
| Soggetto genere / forma |
Internet resource
Periodicals. |
| ISSN | 1476-6256 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
Am J Epidemiol
AJE |
| Record Nr. | UNISA-996203646003316 |
| [Baltimore, Md.], : Johns Hopkins University School of Hygiene and Public Health | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
American journal of epidemiology
| American journal of epidemiology |
| Pubbl/distr/stampa | [Baltimore, Md.], : Johns Hopkins University School of Hygiene and Public Health |
| Descrizione fisica | 1 online resource (volumes) |
| Disciplina | 614 |
| Soggetto topico |
Epidemiology
Public health Epidemiologic Methods Public Health epidemiology public health Épidémiologie Santé publique |
| Soggetto genere / forma |
Internet resource
Periodicals. |
| ISSN | 1476-6256 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
Am J Epidemiol
AJE |
| Record Nr. | UNINA-9910131791603321 |
| [Baltimore, Md.], : Johns Hopkins University School of Hygiene and Public Health | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
| Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance |
| Autore | Organization World Health |
| Pubbl/distr/stampa | Geneva, : World Health Organization, 2014 |
| Descrizione fisica | 1 online resource (254 p.) |
| Disciplina | 616 |
| Soggetto topico |
Drug resistance -- Periodicals
Drug resistance in microorganisms Drug resistance Anti-infective agents - Classification Drug resistance in microorganisms - Effect of drugs on Risk management Risk Risk Management Information Science Drug Resistance Microbiological Phenomena Epidemiologic Measurements Therapeutic Uses Probability Pharmacologic Actions Pharmacological Phenomena Public Health Organization and Administration Statistics as Topic Health Services Administration Environment and Public Health Chemical Actions and Uses Physiological Phenomena Health Care Evaluation Mechanisms Health Care Epidemiologic Methods Drug Therapy Quality of Health Care Investigative Techniques Diagnostic Techniques and Procedures Health Care Quality, Access, and Evaluation Anti-Infective Agents Classification Risk Assessment Drug Resistance, Microbial Biology Health & Biological Sciences Microbiology & Immunology |
| Soggetto genere / forma |
Electronic books.
Publication Formats Technical Report |
| ISBN | 92-4-069266-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Contents; Foreword; Summary; Acknowledgements; Abbreviations; Introduction; SECTION 01 Resistance to antibacterial drugs; 1.1 Background; 1.1.1 Limitations; 1.2 Regional surveillance of antibacterial resistance; 1.2.1 WHO African Region; 1.2.2 WHO Region of the Americas; 1.2.3 WHO Eastern Mediterranean Region; 1.2.4 WHO European Region; 1.2.5 WHO South-East Asia Region; 1.2.6 WHO Western Pacific Region; 1.3 References; SECTION 02 Resistance to antibacterial drugs in selected bacteria of international concern; 2.1 Availability of national resistance data; 2.1.1 Key messages
2.2 Resistance data on specific pathogens2.2.1 Escherichia coli - resistance to third-generation cephalosporins and to fluoroquinolones; 2.2.2 Klebsiella pneumoniae - resistance to third-generation cephalosporins and to carbapenems; 2.2.3 Staphylococcus aureus - resistance to methicillin; 2.2.4 Streptococcus pneumoniae - resistance (non-susceptibility) to penicillin; 2.2.5 Nontyphoidal Salmonella - resistance to fluoroquinolones; 2.2.6 Shigella species - resistance to fluoroquinolones; 2.2.7 Neisseria gonorrhoeae - decreased susceptibility to third-generation cephalosporins; 2.3 References SECTION 03 The health and economic burden due to antibacterial resistance3.1 Methods; 3.2 Findings; 3.2.1 Health burden; 3.2.2 Economic burden; 3.3 Knowledge gaps; 3.4 Key messages; 3.5 References; SECTION 04 Surveillance of antimicrobial drug resistance in disease-specific programmes; 4.1 Tuberculosis; 4.1.1 Evolution of drug resistance in tuberculosis; 4.1.2 Surveillance of drug-resistant tuberculosis; 4.1.3 Global public health response to drug-resistant tuberculosis; 4.1.4 Notification of MDR-TB cases and enrolment on treatment 4.1.5 Public health implications: treatment outcomes for multidrug-resistant and extensively drug-resistant tuberculosis4.1.6 Key messages; 4.2 Malaria; 4.2.1 Evolution of antimalarial drug resistance; 4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance; 4.2.3 Global public health implications of antimalarial drug resistance; 4.2.4 Key messages; 4.3 HIV; 4.3.1 Surveillance of anti-HIV drug resistance; 4.3.2 Global public health implications of anti-HIV drug resistance; 4.3.3 Key messages; 4.4 Influenza; 4.4.1 Evolution of resistance in influenza viruses 4.4.2 Anti-influenza drug resistance4.4.3 Surveillance of anti-influenza drug resistance; 4.4.4 Public health implications of anti-influenza drug resistance; 4.4.5 Key messages; 4.5 References; SECTION 05 Surveillance of antimicrobial resistance in other areas; 5.1 Antibacterial resistance in food-producing animals and the food chain; 5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food; 5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria; 5.1.3 Antimicrobials of particular importance in human and veterinary medicine 5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic material |
| Record Nr. | UNINA-9910511992203321 |
|
Organization World Health
|
||
| Geneva, : World Health Organization, 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
| Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance |
| Autore | Organization World Health |
| Pubbl/distr/stampa | Geneva, : World Health Organization, 2014 |
| Descrizione fisica | 1 online resource (254 p.) |
| Disciplina | 616 |
| Soggetto topico |
Drug resistance -- Periodicals
Drug resistance in microorganisms Drug resistance Anti-infective agents - Classification Drug resistance in microorganisms - Effect of drugs on Risk management Risk Risk Management Information Science Drug Resistance Microbiological Phenomena Epidemiologic Measurements Therapeutic Uses Probability Pharmacologic Actions Pharmacological Phenomena Public Health Organization and Administration Statistics as Topic Health Services Administration Environment and Public Health Chemical Actions and Uses Physiological Phenomena Health Care Evaluation Mechanisms Health Care Epidemiologic Methods Drug Therapy Quality of Health Care Investigative Techniques Diagnostic Techniques and Procedures Health Care Quality, Access, and Evaluation Anti-Infective Agents Classification Risk Assessment Drug Resistance, Microbial Biology Health & Biological Sciences Microbiology & Immunology |
| Soggetto genere / forma |
Publication Formats
Technical Report |
| ISBN | 92-4-069266-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Contents; Foreword; Summary; Acknowledgements; Abbreviations; Introduction; SECTION 01 Resistance to antibacterial drugs; 1.1 Background; 1.1.1 Limitations; 1.2 Regional surveillance of antibacterial resistance; 1.2.1 WHO African Region; 1.2.2 WHO Region of the Americas; 1.2.3 WHO Eastern Mediterranean Region; 1.2.4 WHO European Region; 1.2.5 WHO South-East Asia Region; 1.2.6 WHO Western Pacific Region; 1.3 References; SECTION 02 Resistance to antibacterial drugs in selected bacteria of international concern; 2.1 Availability of national resistance data; 2.1.1 Key messages
2.2 Resistance data on specific pathogens2.2.1 Escherichia coli - resistance to third-generation cephalosporins and to fluoroquinolones; 2.2.2 Klebsiella pneumoniae - resistance to third-generation cephalosporins and to carbapenems; 2.2.3 Staphylococcus aureus - resistance to methicillin; 2.2.4 Streptococcus pneumoniae - resistance (non-susceptibility) to penicillin; 2.2.5 Nontyphoidal Salmonella - resistance to fluoroquinolones; 2.2.6 Shigella species - resistance to fluoroquinolones; 2.2.7 Neisseria gonorrhoeae - decreased susceptibility to third-generation cephalosporins; 2.3 References SECTION 03 The health and economic burden due to antibacterial resistance3.1 Methods; 3.2 Findings; 3.2.1 Health burden; 3.2.2 Economic burden; 3.3 Knowledge gaps; 3.4 Key messages; 3.5 References; SECTION 04 Surveillance of antimicrobial drug resistance in disease-specific programmes; 4.1 Tuberculosis; 4.1.1 Evolution of drug resistance in tuberculosis; 4.1.2 Surveillance of drug-resistant tuberculosis; 4.1.3 Global public health response to drug-resistant tuberculosis; 4.1.4 Notification of MDR-TB cases and enrolment on treatment 4.1.5 Public health implications: treatment outcomes for multidrug-resistant and extensively drug-resistant tuberculosis4.1.6 Key messages; 4.2 Malaria; 4.2.1 Evolution of antimalarial drug resistance; 4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance; 4.2.3 Global public health implications of antimalarial drug resistance; 4.2.4 Key messages; 4.3 HIV; 4.3.1 Surveillance of anti-HIV drug resistance; 4.3.2 Global public health implications of anti-HIV drug resistance; 4.3.3 Key messages; 4.4 Influenza; 4.4.1 Evolution of resistance in influenza viruses 4.4.2 Anti-influenza drug resistance4.4.3 Surveillance of anti-influenza drug resistance; 4.4.4 Public health implications of anti-influenza drug resistance; 4.4.5 Key messages; 4.5 References; SECTION 05 Surveillance of antimicrobial resistance in other areas; 5.1 Antibacterial resistance in food-producing animals and the food chain; 5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food; 5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria; 5.1.3 Antimicrobials of particular importance in human and veterinary medicine 5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic material |
| Record Nr. | UNINA-9910786624203321 |
|
Organization World Health
|
||
| Geneva, : World Health Organization, 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antimicrobial stewardship & healthcare epidemiology : ASHE
| Antimicrobial stewardship & healthcare epidemiology : ASHE |
| Pubbl/distr/stampa | [Cambridge] : , : Cambridge University Press, , [2021]- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
Anti-infective agents
Epidemiology Public health Community health services Social medicine Cross Infection - prevention & control Epidemiologic Methods Anti-Infective Agents Antiinfectieux Épidémiologie Santé publique |
| Soggetto genere / forma |
Periodical
periodicals. Periodicals. Périodiques. |
| ISSN | 2732-494X |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
Antimicrobial stewardship and healthcare epidemiology
ASHE |
| Record Nr. | UNINA-9910508507403321 |
| [Cambridge] : , : Cambridge University Press, , [2021]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
| Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials |
| Autore | Kazmierski Wieslaw M |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (470 p.) |
| Disciplina | 615/.7924 |
| Soggetto topico |
Antiviral Agents -- therapeutic use
Antiviral agents Clinical Trials as Topic Drug Discovery Drug Evaluation Epidemiologic Studies Chemistry, Pharmaceutical Evaluation Studies as Topic Investigative Techniques Anti-Infective Agents Epidemiologic Methods Pharmacology Therapeutic Uses Health Care Evaluation Mechanisms Chemistry Biological Science Disciplines Natural Science Disciplines Quality of Health Care Public Health Pharmacologic Actions Environment and Public Health Health Care Quality, Access, and Evaluation Chemical Actions and Uses Health Care Antiviral Agents Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-283-20363-4
9786613203632 0-470-92935-9 0-470-92934-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate |
| Record Nr. | UNINA-9910139613803321 |
|
Kazmierski Wieslaw M
|
||
| Hoboken, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiviral Drugs : From Basic Discovery Through Clinical Trials
| Antiviral Drugs : From Basic Discovery Through Clinical Trials |
| Autore | Kazmierski Wieslaw M |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (470 p.) |
| Disciplina | 615/.7924 |
| Soggetto topico |
Antiviral Agents -- therapeutic use
Antiviral agents Clinical Trials as Topic Drug Discovery Drug Evaluation Epidemiologic Studies Chemistry, Pharmaceutical Evaluation Studies as Topic Investigative Techniques Anti-Infective Agents Epidemiologic Methods Pharmacology Therapeutic Uses Health Care Evaluation Mechanisms Chemistry Biological Science Disciplines Natural Science Disciplines Quality of Health Care Public Health Pharmacologic Actions Environment and Public Health Health Care Quality, Access, and Evaluation Chemical Actions and Uses Delivery of Health Care Antiviral Agents Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-283-20363-4
9786613203632 0-470-92935-9 0-470-92934-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate |
| Record Nr. | UNINA-9910808713803321 |
|
Kazmierski Wieslaw M
|
||
| Hoboken, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Epidemiologic Methods
(164)
- Public Health (128)
- Environment and Public Health (120)
- Investigative Techniques (120)
- Quality of Health Care (117)